Advanced drug delivery formulations stories

Nov 5, 2026

FDA grants J&J accelerated approval for head and neck cancer treatment

The FDA granted accelerated approval to Johnson & Johnson's treatment for patients with advanced head and neck cancer whose disease has worsened after prior therapy.

Nov 5, 20262 sources

Top claims

▪Intravenously infused Rybrevant received its initial FDA approval in 2021 for treating non-small cell lung cancers harboring an EGFR mutation
▪Rybrevant is a bispecific antibody designed to block EGFR and MET, two receptors overexpressed in certain cancers, to overcome single-target treatment resistance
▪For the first nine months of 2026, Johnson & Johnson reported $866 million in global Rybrevant/Lazcluze sales, representing a 67.4% year-over-year increase

Subtopics

Accelerated approval pathways1 Biologic therapies1 Cancer & Oncology1 Clinical trials1 Drug Policy, Pricing & Approval1 FDA drug approval1 Targeted cancer therapy1

Related timelines